The following statement is WRONG regarding Hepatitis B Vaccination?

RML Lucknow - 2021

Pharmacology

Easy

Appeared in: RML Lucknow - 2021

Explanation

The statement that the Hepatitis B vaccine should be administered subcutaneously is incorrect.
The correct and recommended route of administration for the Hepatitis B vaccine is intramuscular (IM).
IM injection ensures optimal absorption and stimulates a robust immune response.
The recommended injection site is the anterolateral aspect of the thigh for infants and the deltoid muscle for older children and adults.
Subcutaneous administration is avoided because it can result in a weaker immune response and a higher incidence of local adverse reactions, such as pain, induration, and sterile abscesses.

Option A: This is a correct statement. The World Health Organization (WHO) and national immunization programs recommend administering the first dose of the Hepatitis B vaccine to all newborns as soon as possible after birth, preferably within 24 hours, to prevent perinatal transmission.
Option C: This is a correct statement. Due to the occupational risk of exposure to blood and other potentially infectious materials, vaccination against Hepatitis B is a standard and essential safety measure for all healthcare workers.
Option D: This is a correct statement. A complete primary series of the Hepatitis B vaccine (typically three doses) induces protective antibody concentrations in more than 95% of healthy infants, children, and young adults, conferring long-term, and in most cases, lifelong immunity.

Clinical Relevance

Nursing practice connection: This is primarily an exam-oriented knowledge point with limited direct bedside application, so retain Hepatitis B Vaccination Administration and Schedule as background academic context rather than a clinical decision trigger.
A nurse's primary responsibility includes adhering to the 'five rights' of medication administration, which prominently features the 'Right Route'. Administering the Hepatitis B vaccine via the correct IM route is critical for ensuring vaccine efficacy and patient safety.
Incorrect administration (e.g., subcutaneous or into the gluteal fat) can lead to vaccine failure, leaving the patient unprotected against Hepatitis B infection.
What if? If a patient has a severe bleeding disorder like hemophilia, the vaccine might be given subcutaneously to reduce the risk of a hematoma. However, this is a specific clinical exception, and the standard, recommended route for the general population remains intramuscular.

How to Approach the Question

First, recognize that the question asks for the 'WRONG' statement. This means you are searching for the single false option among three true statements.
Systematically evaluate each option against your knowledge of standard vaccination protocols.
Focus on the core components of vaccine administration: timing (newborn dose), route (subcutaneous vs. intramuscular), target populations (healthcare workers), and efficacy (immunity duration).
Recall that most inactivated vaccines, including Hepatitis B, are administered intramuscularly to maximize the immune response. The subcutaneous route is typically reserved for certain live vaccines.
Confirm that the statements about the birth dose, vaccination for healthcare workers, and lifelong immunity are all well-established, correct principles of Hepatitis B prevention.
This process of elimination will clearly identify the statement about subcutaneous administration as the incorrect one.

Concept Tested & Keywords

Concept Tested: Hepatitis B Vaccination Administration and Schedule
Stem keywords: Hepatitis B Vaccination, newborn, health care workers, immunity
Lead-in keywords: WRONG
Negative lead-in flag: The question asks for the INCORRECT statement (a 'negative' stem). This means three of the options are true facts about Hepatitis B vaccination, and your task is to find the one that is false.

Q2vb-rsSUzsoGwp92qxcxE

E6 Parks TextBook of Preventive & Social Medicine part 1 — Subpart B (pp 202-403 of 604) p. 67-69

E6 Medicine Harrison 22e Part 2 pp. 568-570, 567-569